Foshan Ampoz Biomedical

Foshan Ampoz Biomedical is a China-based biotechnology company dedicated to the research, development, and industrialization of biosimilars and innovative antibody drugs. Established in 2015 within the Foshan National High-tech Zone, the company has built a robust pipeline targeting high-prevalence conditions in oncology, immunology, and ophthalmology. Its lead programs include biosimilar versions of blockbuster drugs such as Prolia (denosumab), Humira (adalimumab), and Xolair (omalizumab), many of which have reached Phase 3 clinical trials. Ampoz operates a large-scale GMP-compliant manufacturing facility to support its transition from a research-oriented entity to a commercial-stage pharmaceutical company. By focusing on cost-effective biologics, the company aims to improve patient access to critical therapies both in China and internationally.